Overall, we observed that the expression of the activation markers CD38 and HLA-DR on MTB-specific CD4+ T-cells was significantly reduced after 6 months of TB treatment (p = 0.003 for CD38, p = 0.0027 for HLA-DR and p = 0.0020 for Ki67), and all these markers were already significantly reduced at month 2. The gene discussed is MKI67; the disease is tuberculosis.